ASIC1a, a new therapeutic drug target for cardiac ischemia

ASIC1a，心脏缺血的新治疗药物靶点

• 批准号: nhmrc : 2002857
• 金额: $ 138.22万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/asic1a-new-therapeutic-cardiac-ischemia/1780005
• 关键词: ASIC1a; new; therapeutic; drug; target

Cardiovascular disease is the biggest killer in the world, in large part due to the lack of drugs to protect the heart from the damage caused by injuries such as heart attack. Our team of world-leading scientists and clinicians has identified a novel therapeutic target (ASIC1a) against which drugs could be targeted to protect the heart against these injuries. The aim of this project is to develop novel cardioprotective drugs that target ASIC1a so we can test them in human clinical trials.

心血管疾病是世界上最大的杀手，在很大程度上是由于缺乏药物来保护心脏免受心脏病发作等伤害造成的损害。我们的世界领先的科学家和临床医生团队已经确定了一种新的治疗靶点（ASIC1a），药物可以针对该靶点保护心脏免受这些损伤。该项目的目的是开发针对ASIC1a的新型心脏保护药物，以便我们可以在人体临床试验中对其进行测试。